Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Rev. ciênc. farm. básica apl ; 41: [13], 01/01/2020. tab, graf
Article in English | LILACS | ID: biblio-1128583

ABSTRACT

Aim: Since other species of the Bignoniaceae Family presented of antispasmodic activity, it was decided, by chemotaxonomic criterion, to determine the antispasmodic activity of the leaves of Arrabidaea brachypoda. Methodology: the segments of the rat jejunum were suspended in glass vats containing specific saline solution, at an appropriate temperature, and after stabilization period, were stimulated by a contractile agent to observe the inhibitory or relaxing effect of EH-FAB. Results: EH-FAB showed the presence of 10 compounds, mainly rutin and it has an antispasmodic activity as it inhibits the phasic component and relaxes the tonic component of the contraction in isolated rat jejunum. To assess the mechanism of antispasmodic action, cumulative curves to the CCh were performed in which a non-competitive antagonism was observed, due to a displacement of the control curve to the right and reduction of the maximum contraction effect (Emax). Afterward, the participation of the calcium and/or potassium channels was evaluated by increasing the extracellular potassium, and it was observed that the EH-FAB relaxed the rat jejunum, suggesting the participation of the Ca2+ channels. To corroborate that hypothesis, the EH-FAB was tested against cumulative curves to Ca2+ in a free depolarizing solution of Ca2+, and it was observed that there was a shift of the curve to the right with a reduction in Emax. Conclusions: EH-FAB presents antispasmodic activity in isolated rat jejunum and it is suggested to block the influx of Ca2+ through voltage-gated calcium channels, signaling the therapeutic potential for the treatment of colic and/or diarrhea.(AU)


Subject(s)
Animals , Male , Rats , Parasympatholytics/therapeutic use , Plant Extracts/pharmacology , Calcium Channel Blockers/pharmacology , Bignoniaceae/chemistry , Potassium , Jejunum
2.
Evid. actual. práct. ambul ; 23(1): e002045, 2020. tab
Article in Spanish | LILACS | ID: biblio-1103172

ABSTRACT

Una mujer de 36 años, diagnosticada con síndrome de intestino irritable a predominio de diarrea (SII-D) acude a la consulta médica. Ella pregunta si el uso de probióticos sería útil para controlar los episodios de diarrea, ya que los fármacos con los que está siendo tratada no le resultan eficaces. Se realizó una búsqueda bibliográfica con el objetivo de en contrar evidencia en respuesta a su consulta, tras la cual se seleccionaron dos ensayos clínicos y una revisión sistemática. Se evidenciaron diversos resultados en cuanto al uso de probióticos en el SII-D y se discutieron los riesgos y beneficios del tratamiento, así como las implicancias en la vida de la paciente. (AU)


A 36-year-old woman diagnosed with diarrhea predominant irritable bowel syndrome (D-IBS) goes to meet the doctor. She raises whether the use of probiotics would be useful for controlling diarrhea episodes, since the drugs which she is being treated with, are not effective. A bibliographic search was conducted with the objective of finding evidence in response toher query. Two clinical trials and a systematic review were found. Variable results were found regarding the use of probioticsin D-IBS. The risks and benefits of the treatment were discussed, as well as the implications in the patient's lifestyle. (AU)


Subject(s)
Humans , Female , Adult , Probiotics/therapeutic use , Irritable Bowel Syndrome/therapy , Diarrhea/therapy , Parasympatholytics/therapeutic use , Quality of Life , Review Literature as Topic , Abdominal Pain/therapy , Cholestyramine Resin/therapeutic use , Clinical Trials as Topic , Probiotics/administration & dosage , Probiotics/adverse effects , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/etiology , Diarrhea/complications , Duration of Therapy , Gastrointestinal Motility/immunology , Intestinal Mucosa/immunology , Loperamide/therapeutic use , Antidepressive Agents/therapeutic use
4.
Article in Korean | WPRIM | ID: wpr-171345

ABSTRACT

BACKGROUND/AIMS: Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. METHODS: A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. RESULTS: At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. CONCLUSIONS: Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.


Subject(s)
Abdominal Pain/etiology , Adult , Constipation/etiology , Diarrhea/etiology , Double-Blind Method , Drug Administration Schedule , Female , Humans , Irritable Bowel Syndrome/complications , Male , Middle Aged , Parasympatholytics/therapeutic use , Phenothiazines/therapeutic use , Severity of Illness Index , Treatment Outcome , Trimebutine/therapeutic use
5.
Rev. gastroenterol. Perú ; 32(4): 387-393, oct.-dic. 2012. ilus, tab
Article in Spanish | LIPECS, LILACS, LIPECS | ID: lil-692407

ABSTRACT

El Sindrome de Intestino Irritable (SII), es un transtorno funcional muy común y causa frecuente de consulta en gastroenterología, su fisiopatología es multifactorial y se caracteriza por dolor abdominal, distensión y alteración de los hábitos defecatorios, su terapia es básicamente sintomática (loperamida, antiespasmódicos, antidepresivos,etc).Recientemente se ha incorporado al tratamiento, el uso de probióticos que podrían mejorar su sintomatología. POBLACIÓN Y MÉTODO: Ensayo Clínico doble ciego aleatorizado simple, multicentrico que incluyó pacientes con diagnóstico de SII basado en criterios de Roma III. A estos se les administró Bromuro de Pinaverio mas placebo o Bromuro de Pinaverio mas Probiótico. La intensidad de los síntomas y el efecto del tratamiento fue valorado de acuerdo a Score de Francis antes y al final del tratamiento. Los cálculos fueron hechos con el programa SPSS 12.0.IC 95% RESULTADO. Se evaluaron 51 pacientes con promedio de edad de 43 años, mayoritariamente mestizos, 75%(38) casados y 55%(28) del sexo femenino, se encontró diferencias significativas en 4 variables de comparación: Dolor abdominal, Severidad del dolor, Días de dolor, y el Score total al final del tratamiento. CONCLUSIONES Los Probióticos utilizados como suplemento son efectivos en mejorar la sintomatología del SII.


Background: Irritable bowel syndrome (IBS) is a very common functional condition and a frequent cause of consultation in gastroenterology. With a multifactorial pathophysiology IBS is characterized by abdominal pain, distension and altered bowel habits. Loperamide, antispasmodics and antidepressants are symptomatic relievers of this disorder. Recently probiotics were incorporated to therapy, and could improve the symptomatology. Methods: multicenter randomized placebo-controlled trial that included IBS patients, diagnosed with Rome III criteria. The patients were given pinaverium bromure and placebo or pinaverium bromure and probiotics for 3 weeks. The intensity of symptoms and the effect of therapy were evaluated with the Francis Score, before and after the treatment. Statistics were done with SPSS 12.0 (C.I 95%). Results: 51 patients were evaluated, with an average age of 43 years old, mostly mestizo, 75% (38) married and 55% (28) female. There were statistical differences in four variables: abdominal pain, intensity of pain, days of pain and total score at the end of therapy. Conclusions: Probiotics used as supplement are effective in improving symptomatology of IBS.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Irritable Bowel Syndrome/therapy , Probiotics/therapeutic use , Combined Modality Therapy , Double-Blind Method , Drug Administration Schedule , Follow-Up Studies , Lactobacillus acidophilus , Morpholines/therapeutic use , Parasympatholytics/therapeutic use , Prospective Studies , Severity of Illness Index , Treatment Outcome
6.
Article in Korean | WPRIM | ID: wpr-11780

ABSTRACT

Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT4 receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.


Subject(s)
Anti-Infective Agents/therapeutic use , Antidepressive Agents/therapeutic use , Antidiarrheals/therapeutic use , Dietary Fiber/therapeutic use , Humans , Irritable Bowel Syndrome/therapy , Laxatives/therapeutic use , Parasympatholytics/therapeutic use , Probiotics/therapeutic use , Serotonin 5-HT4 Receptor Agonists/therapeutic use , Serotonin Antagonists/therapeutic use
7.
Col. med. estado Táchira ; 18(1): 39-42, ene.-mar. 2009. ilus, tab
Article in Spanish | LILACS | ID: lil-530712

ABSTRACT

Los tricobezoar son recolecciones de material ingerido (pelos, fibras) que se acumulasn en estómago e intestino. Se originan de la tricotilomanía más tricofagia, cuando el tricobezoar se acumula en duodeno recibe el nombre de Sídrome de Rapunzel, más frecuente en el sexo femenino. Adolescente de 15 años, quien presentó dolor abdominal de aparición insidiosa acompañada de naúseas y vómitos incontables que se irradian a hipocondrio y fosa iliaca izquierda, su evolución fue torpida presentando signos de irritación peritoneal. Se realiza laparatomía exploradora hallándose tumor de contenido de pelo a nivel del Ángulo de Treitz, y cámara gástrica. Siendo egresada y referida al servicio de psiquiatría infanto-juvenil.


Subject(s)
Humans , Adolescent , Female , Albendazole/administration & dosage , Bezoars/diagnosis , Bezoars/pathology , Dehydration/diagnosis , Abdominal Pain/diagnosis , Intestine, Small/pathology , Laparotomy/methods , Metronidazole/administration & dosage , Trichotillomania/pathology , Vomiting/diagnosis , Adolescent Psychiatry , Albendazole/pharmacology , Foreign Bodies , Gastroenterology , Metronidazole/pharmacology , Parasympatholytics/therapeutic use
8.
Rev. cuba. med. gen. integr ; 22(2)abr.-jun. 2006. tab
Article in Spanish | LILACS | ID: lil-478696

ABSTRACT

Los medicamentos constituyen la tecnología médica más utilizada en el mundo contemporáneo. La prescripción de un medicamento no debe ser considerado como un acto reflejo, una receta de cocina o una respuesta a las presiones comerciales o de los pacientes. Se aplicó una encuesta anónima a 450 pacientes medicados con espasmoforte para describir el uso de este fármaco en el Cuerpo de Guardia. La prescripción del medicamento fue elevada y relacionada erróneamente con la cefalea migrañosa. El costo del sobreuso es elevado y necesita ser más racional y eficaz su prescripción.


Subject(s)
Humans , Parasympatholytics/adverse effects , Parasympatholytics , Parasympatholytics/therapeutic use
9.
Rev. cuba. plantas med ; 9(3)sept.-dic. 2004.
Article in Spanish | LILACS | ID: lil-401129

ABSTRACT

Se realizaron 3 experimentos con el objetivo de validar la propiedad espasmolítica de la Melissa officinalis L., descrita por la medicina popular. El primero, in vitro, consistió en la evaluación de la respuesta de la Melissa en íleon aislado de cobayo, frente a las contracciones inducidas por diferentes espasmógenos. Un experimento in vivo evaluó la actividad del tránsito intestinal en ratones y en el otro se aplicó un modelo de diarreas en ratas. En todos los modelos se utilizó etanol como menstruo. Se empleó papaverina como control positivo. La Melissa officinalis mostró acción antiespasmódica en los 3 estudios realizados


Subject(s)
Animals , Guinea Pigs , Mice , Rats , In Vitro Techniques , Medicine, Traditional , Melissa , Models, Animal , Parasympatholytics/therapeutic use , Phytotherapy , Plant Extracts , Plants, Medicinal
10.
Yonsei Medical Journal ; : 644-651, 2002.
Article in English | WPRIM | ID: wpr-156714

ABSTRACT

Various methods of treatment, other than antibiotic therapy, have been proposed for the treatment of female urethral syndrome; however, the results of these treatment methods are disappointing, due perhaps to the use of the wrong treatment approach. The aim of this study was to evaluate the effectiveness of external sphincter relaxant and biofeedback (BFB) with electrical stimulation therapy (EST) in patients who do not respond well to antibiotics. One hundred and five patients with a diagnosis of female urethral syndrome were entered into this study. Antibiotics were given as a first-line therapy for about 3 months. In cases of recurrent or incurable urethral syndrome, antibiotic therapy combined with external sphincter relaxant or BFB with EST were performed. External sphincter relaxant group was composed of 31 patients (29.5%) who showed functional urethral obstruction. Biofeedback group was composed of 41 patients (39.0%) who had severe pain or discomfort with irritative voiding symptoms. Subjective symptom was measured before and after therapy using the Bristol Female Lower Urinary Tract Symptoms questionnaire. Thirty-three patients (31.4%) were treated with antibiotic therapy alone and 7 (21.2%) of these patients recurred. The symptom score of this group changed from 10.51 to 2.85. In the antibiotics plus external sphincter relaxant group (N=31), the symptom score changed from 12.39 to 3.96. Five (16.1%) of these patients recurred and 3 of these 5 underwent urethral dilatation. In the antibiotics plus biofeedback group (N=41), the average urinary frequency changed from 12.2 to 7.7 times a day and nocturia changed from 2.4 to 0.6 times a night. The symptom score improved from 15.22 to 4.69 and the overall satisfaction rate was 87.8% (41.5%: very satisfied, 46.3%: satisfied, 12.2%: no response). Female urethral syndrome is not due to a single factor but is a complex disease due to various combined symptoms and mechanisms. This condition needs to be treated with an appropriate treatment protocol. We believe that satisfactory results could be obtained in female urethral syndrome, which has shown poor prognosis until now, by appropriately combining treatment methods, which include the use of external sphincter relaxants, biofeedback therapy and bladder training, according to indication, and depending on whether symptoms continue after initial antibiotic therapy.


Subject(s)
Adult , Aged , Anti-Bacterial Agents/therapeutic use , Biofeedback, Psychology , Electric Stimulation Therapy , Female , Humans , Middle Aged , Parasympatholytics/therapeutic use , Urethral Diseases/etiology
11.
Rev. cuba. plantas med ; 6(1): 12-15, 2001. tab
Article in Spanish | LILACS | ID: lil-329981

ABSTRACT

Para validar científicamente la actividad antiespasmódica del Piper auritum H.B.K., se preparó el aceite esencial al 1 por ciento y se evaluó en el modelo de motilidad espontánea de yeyuno aislado de conejo a las concentraciones de 2, 3 y 5 mg/mL frente a diferentes espasmógenos (cloruro de bario 200, acetilcolina 0,06 e histamina 0,05 mg/10-3/mL) en íleon de curiel con valores de 1, 2 y 3 mg/mL. La papaverina se empleó a las concentraciones de 0,0033; 0,0066 y 0,013 mg/mL. Con los resultados obtenidos se puede plantear que la planta tiene actividad espasmolítica sobre el músculo liso intestinal


Subject(s)
Herbal Medicine , Intestines , Muscle, Smooth/anatomy & histology , Plant Extracts , Plants, Medicinal , Acetylcholine , Papaver , Parasympatholytics/therapeutic use
12.
Rev. cuba. plantas med ; 6(1): 19-22, 2001. tab
Article in Spanish | LILACS | ID: lil-329983

ABSTRACT

Para validar la actividad espasmolítica del P. auritum H.B.K. en el intestino, se prepararon los extractos al 45 y 80 por ciento y se evaluaron en el modelo de motilidad espontánea de yeyuno aislado de conejo a las concentraciones de 0,48; 0,7275 y 0,97 mg/mL para el extracto al 45 por ciento y 0,0699;0,1398 y 0,2097 mg/mL para el de 80 por ciento, frente a diferentes espasmógenos (BaCl 200, acetilcolina 0,06 e histamina 0,05 mg/10-3/mL) en íleon de curiel con valores similares. La papaverina se empleó con 0,0033; 0,0066 y 0,013 mg/mL. Un modelo in vivo para medir la actividad sobre el tránsito intestinal con la dosis de 500, 1 000 y 1 500 para el extracto al 45 por ciento, de 10, 40 y 80 con papaverina y 0,5, 1 y 1,5 mg/mL para la atropina. Con los resultados se puede plantear que la planta tiene acción espasmolítica en el intestino


Subject(s)
Herbal Medicine , Intestines , Parasympatholytics/therapeutic use , Plant Extracts , Plants, Medicinal
14.
J Indian Med Assoc ; 1999 Sep; 97(9): 398-400
Article in English | IMSEAR | ID: sea-105761

ABSTRACT

To study the efficacy and safety of a parenteral formulation of 'Manyana' (a combination of diclofenac + pitofenone + fenpiverinium) in ureteric, biliary and intestinal colic, an open labelled study was conducted at two centres. A total of 206 patients were enrolled and evaluated for decrease in pain with time on a visual analogue scale. A statistically significant difference was observed in pain within 30 minutes of drug administration and the pain relief lasted for as long as 24 hours post dosing. The study shows definite synergism between the antispasmodics pitofenone and fenpiverinium with the NSAID-diclofenac, reducing the prostaglandin levels and also the spasm related to colic.


Subject(s)
Adolescent , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Benzophenones/therapeutic use , Biliary Tract Diseases/drug therapy , Colic/drug therapy , Diclofenac/therapeutic use , Drug Combinations , Female , Humans , Injections, Intramuscular , Intestinal Diseases/drug therapy , Male , Middle Aged , Parasympatholytics/therapeutic use , Piperidines/therapeutic use , Ureteral Diseases/drug therapy
15.
J Indian Med Assoc ; 1999 Jun; 97(6): 244-5
Article in English | IMSEAR | ID: sea-104845

ABSTRACT

In this double blind, prospective study, the relative efficacy of Diclofenac + Pitofenone + Fenpiverinium (Manyana) and Analgin + Pitofenone + Fenpiverinium (Baralgan) in 200 patients of biliary, ureteric and intestinal colic was evaluated. Patients were given these coded drugs thrice daily for five days starting from day 0 to day 5. The results of the present clinical evaluation demonstrated that Manyana appeared to be superior to Baralgan in biliary and ureteric colic while it was therapeutically equivalent to Baralgan in reducing the pain intensity in intestinal colic. Both the medications were tolerated well and there were no side-effects reported.


Subject(s)
Adolescent , Adult , Benzophenones/therapeutic use , Biliary Tract Diseases/drug therapy , Colic/diagnosis , Diclofenac/therapeutic use , Dipyrone/therapeutic use , Double-Blind Method , Drug Combinations , Female , Humans , Intestinal Diseases/drug therapy , Male , Middle Aged , Pain Measurement , Parasympatholytics/therapeutic use , Piperidines/therapeutic use , Prospective Studies , Time Factors , Ureteral Diseases/drug therapy
17.
Bangladesh Med Res Counc Bull ; 1998 Apr; 24(1): 6-9
Article in English | IMSEAR | ID: sea-358

ABSTRACT

Extract of Nelumbo nucifera rhizome (RNN) was used as anti-diarrheal agent to combat the diarrhea in experimental rats. The RNN extract in graded doses (100, 200, 400 and 600 mg/kg body wt.) reduced not only the frequency of defecation, wetness of fecal dropping and PGE2 induced enteropooling but also the propulsive movements of charcoal meal significantly.


Subject(s)
Administration, Oral , Animals , Antidiarrheals/therapeutic use , Atropine/therapeutic use , Cathartics/therapeutic use , Cecum/drug effects , Diarrhea/drug therapy , Dinoprostone/pharmacology , Female , Gastrointestinal Motility/drug effects , Intestinal Mucosa/drug effects , Intestinal Secretions/drug effects , Male , Parasympatholytics/therapeutic use , Phytotherapy , Plant Extracts/administration & dosage , Plant Roots/therapeutic use , Plants, Medicinal/therapeutic use , Pylorus/drug effects , Rats , Rats, Long-Evans , Tragacanth/therapeutic use
18.
Ginecol. obstet. Méx ; 66(1): 35-9, ene. 1998. tab, ilus
Article in Spanish | LILACS | ID: lil-232516

ABSTRACT

Fue realizado un estudio clínico longitudinal abierto, no comparativo, en 30 mujeres con diagnóstico de dismenorrea primaria o secundaria a dispositivo intrauterino. El objetivo del estudio fue evaluar la eficacia y seguridad del compuesto terapéutico, Clonixinato de lisina y Bromuro de butihioscina 125 y 10 mg respectivamente, en cápsulas, durante un periodo de observación de tres ciclos menstruales. El tiempo de evolución de la dismenorrea primaria fue de 4.46 años; para la secundaria fue de 1.77 años. A la dismenorrea le acompañaron síntomas asociados como: náusea 92 por ciento, vómito 92 por ciento, malestar general 82.1 por ciento, pesantez abdominales 85.7 por ciento y cefalea 46.4 por ciento. Respecto a la intensidad del dolor menstrual, al inicio fue muy severo en el 10.7 por ciento, severo en 42.9 por ciento y moderado 46.4 por ciento. Al final del estudio sólo una paciente de las 28, presentó dolor menstrual de intensidad moderada. Encontramos sólo tres menciones de efectos secundarios de intensidad leve y que no requirieron tratamiento; que correspondieron a dos menciones de gastralgía y una de somnolencia. La conclusión del estudio es que la asociación analgésica espasmolítica del Clonixinato de lisina y Bromuro de butilhioscina en el tratamiento de la dismenorrea primaria o secundaria, reduce y previene el dolor menstrual, así como las manifestaciones asociadas con pocos efectos secundarios. Esta asociación analgésica espasmolítica, es eficaz y segura


Subject(s)
Humans , Female , Adolescent , Adult , Administration, Buccal , Analgesics/therapeutic use , Muscarinic Antagonists/administration & dosage , Muscarinic Antagonists/therapeutic use , Butylscopolammonium Bromide/administration & dosage , Butylscopolammonium Bromide/therapeutic use , Clonixin/administration & dosage , Clonixin/analogs & derivatives , Clonixin/therapeutic use , Cyclooxygenase Inhibitors/administration & dosage , Cyclooxygenase Inhibitors/therapeutic use , Dysmenorrhea/drug therapy , Longitudinal Studies , Lysine/administration & dosage , Lysine/analogs & derivatives , Lysine/therapeutic use , Menstrual Cycle , Parasympatholytics/administration & dosage , Parasympatholytics/therapeutic use
19.
Arch. Inst. Cardiol. Méx ; 67(3): 227-30, mayo-jun. 1997. tab
Article in Spanish | LILACS | ID: lil-217302

ABSTRACT

Objetivo: Demostrar la eficacia terapéutica del bromuro de propantelina para evitar recurrencia en síncope vagotónico. Lugar: HGZ No. 3 IMSS, Mazatlán, Sinaloa, México de 1992 a 1995. Pacientes: De 41 pacientes con síncope se incluyeron 10 con síncope vagotónico. Diseño: longitudinal prospectivo. Procedimiento: Se realizó historia clínica, valoración cardiológica y neurológica, electrocardiograma, electroencefalograma, T.A.C., Holter, prueba de esfuerzo y Rx de tórax. Se realizó seguimiento de 10 pacientes por espacio de 12 meses y se midió recurrencia, mejoría de síntomas clínicas y efectos colaterales de bromuro de propantelina 15 a 30 mg cada 8 horas vía oral. Resultados: De 10 pacientes 7 son mujeres, edad promedio 18 años, no hubo recurrencia de síncope en 9 de ellos (p < 0.005), 1abandodó tratamiento, 4 con efectos colaterales leves. Conclusiones: El bromuro de propantelina disminuye la recurrencia de síncope vagotónico con pocos efectos colaterales a 1 año de seguimiento


Subject(s)
Humans , Male , Female , Adolescent , Adult , Parasympatholytics/therapeutic use , Propantheline/therapeutic use , Prospective Studies , Syncope , Syncope, Vasovagal
20.
Rev. guatemalteca cir ; 5(3): 96-8, sept.-dic. 1996. ilus
Article in Spanish | LILACS | ID: lil-200207

ABSTRACT

Se trató con cloruro de oxibutinina, una muestra 40 pacientes con inestabilidad vesical, diagnosticada desde los puntos de vista clínico y urodinámico. A todos se les administró de 10-15 mgs./día de cloruro de oxibutinina, por una media de 12 meses (8-18 meses). El tratamiento y seguimiento, fue valorado tras un período de 6-38 meses (media de 20 meses). Desde el punto de vista clínico se obtuvo mejoría total en un plazo de tratamiento de 3 meses, en 20 pacientes (50/100) mejoría relativa con desaparición de algunos de los síntomas o disminución de intensidad de los previos en 18(45/100). No se obtuvo mejoría en 2 pacientes (5/100) Obtuvimos una mejoría global y relativa del 95/100. Desde el punto de vista urodinámico, desaparecieron los signos de inestabilidad de forma total en los 5 pacientes en que se efectuó control urodinámico. Entre los efectos secundarios encontrados, 38 pacientes manifestaron sequedad de boca, 5 pacientes náusea y vómitos, en 10 casos fue necesario reducir la dosis diaria de 15 a 10 mg.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Parasympatholytics/therapeutic use , Urinary Bladder, Neurogenic/diagnosis , Urinary Bladder, Neurogenic/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL